We are thrilled to announce that as of October 30th, we have successfully completed the prospective recruitment for the EORTC SPECTA IMMUcan cohort!
This incredible journey began five years ago with the enrolment of our first patient in June 2019. Today, we proudly celebrate reaching our goal of enrolling 1,472 patients.
Thanks to external collaborations, the total number of patients analysed in IMMUcan will reach 2,650, all of whom will undergo comprehensive molecular and cellular profiling.
A heartfelt thank you to all the patients and investigators whose dedication and involvement made this remarkable achievement possible!
The analysis of all the generated data will continue next year. Stay tuned for more updates!
